12:00 AM
 | 
May 07, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Copaxone glatiramer acetate: Interim data

Interim data from 52 of 110 patients with spasticity in an open-label, prospective survey study showed that switching to Copaxone from beta interferon therapy led to significant reductions from baseline to 6 months in muscle stiffness (p=0.001), pain and discomfort (p=0.009),...

Read the full 184 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >